Observational studyThe oncologist2026

MEK inhibitor-based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations.

Elizabeth D Auckley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.